Mode
Text Size
Log in / Sign up
Phase 4 Completed N=16 Randomized Other

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)

Source: ClinicalTrials.gov NCT00915538 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: The Mean Area Under the Curve (AUC) of Forced Expiratory Volume in One Second (FEV-1) Over 12 Hours, Measured (BL), 5, 10, 15, 60, 120, 240, 480, 720 Minutes. The Unit is Liters, and the AUC is in Liters. — 2.77; 2.79 Liters X hours — p=0.76
◆ Published Evidence
Emerging
5citations · ~0 / year
A valved holding chamber does not decrease the bronchodilator activity of budesonide-formoterol combination metered dose inhaler.
The Journal of asthma : official journal of the Association for the Care of Asthma · 2013 · Likely link

Summary

This study will compare the amount of bronchial tube relaxation from the Formoterol medicine contained in the Symbicort pressure Metered Dose Inhaler(pMDI)(a combination of Budesonide, a steroid, and Formoterol, a drug which relaxes the bronchial smooth muscle. The comparison will be using the pMDI in the usual fashion to the pMDIs and a spacer which allows more time for breathing in the medication. Breathing tests will be measured over a 12 hour period for the comparison.

Linked Publications

  • A valved holding chamber does not decrease the bronchodilator activity of budesonide-formoterol combination metered dose inhaler.
    The Journal of asthma : official journal of the Association for the Care of Asthma · 2013 · 5 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
The Mean Area Under the Curve (AUC) of Forced Expiratory Volume in One Second (FEV-1) Over 12 Hours, Measured (BL), 5, 10, 15, 60, 120, 240, 480, 720 Minutes. The Unit is Liters, and the AUC is in Liters.
2.77; 2.79 0.76
SECONDARY
FEV-1/FVC
76.13; 75.58; 79.08; 79.91; 78.55; 81.16 0.76

Eligibility Criteria

Inclusion Criteria

  • Asthma with 15% or more increase in Forced expiratory volume at 1 second (FEV-1) after 180-360 mcg of albuterol pMDI

Exclusion Criteria

  • Any illness or condition which might place subject at risk in the study;e.g. some cardiovascular disorders Inability to understand and sign informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00915538) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search